In line with previous studies showing the upregulation of CDKN2B‐AS1 in various solid tumours, such as kidney [35], laryngeal squamous cell [36], ovarian [37], thyroid [30] and liver [38] cancers, elevated CDKN2B‐AS1 levels have been linked to advanced TNM stages or poor prognoses in these cancer types. This evidence concerns the gene CDKN2B and cancer.